Insulet (NSDQ:PODD) shares are under pressure this morning after the diabetes company missed expectations for its 4th-quarter earnings, despite beating Wall Street’s consensus sales forecast. Billerica, Mass.-based Insulet narrowed its losses by -66.6%, to -$9.1 million, or -16¢ per share, on sales growth of 23.6% to $103.6 million for the 3 months ended Dec. 31, compared […]
Insulet
Insulet touts Omnipod Horizon hybrid closed-loop system in patients with T1D
Insulet (NSDQ:PODD) touted data today from the 1st feasibility study of its Omnipod Horizon hybrid closed-loop system in patients with Type 1 diabetes. Data from the study showed that the Omnipod automated glucose control algorithm performed well, with minimal hypoglycemia, and that it was safe. The Billerica, Mass.-based company enrolled 24 patients with Type 1 diabetes […]
Update: Insulet opens manufacturing facility in Acton, Mass.
Insulet (NSDQ:PODD) said yesterday that it acquired a manufacturing facility in Acton, Mass. The Billerica, Mass.-based company said that its new facility will allow Insulet to more efficiently manufacture its OmniPod system compared to 4 of the company’s manufacturing lines at its contract manufacturer in China. The company anticipates the new facility will add hundreds of jobs in Massachusetts […]
Analyst: Insulet’s drug-delivery biz a long-term growth driver
Insulet’s (NSDQ:PODD) drug-delivery business will be a long-term growth driver for the company by as much as 20% a year for the next few years, according to Leerink Partners analysts. Billerica, Mass.-based Insulet generates 86% of its revenue from its OmniPod insulin delivery device, according to Leerink. The OmniPod technology could be easily adapted to […]
